+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating clemizole HCl as an additional treatment for children and adults with Lennox-Gastaut syndrome LGS, a severe form of epilepsy. This phase 3 study is randomized, double-blind, and placebo-controlled, aiming to assess both the safety and effectiveness of clemizole HCl when added to current therapies. The study includes an Observational Period, a Double-Blind Period, and an optional Open-Label Extension Period to gather comprehensive data over time. Participants will be randomly assigned to receive either clemizole HCl or a placebo, both given as oral solutions. After completing the Double-Blind Period, eligible participants may choose to continue treatment with clemizole HCl in the Open-Label Extension Period for up to three years. This design helps researchers compare outcomes between the study drug and placebo, and to observe long-term effects of clemizole HCl. During the study, participants will be monitored regularly to measure changes in seizure frequency and severity, using tools like the CMMS-28 scale. Other assessments include global impression scores from clinicians and caregivers, quality of life evaluations, and safety monitoring for adverse events. The primary outcome focuses on seizure changes over 16 weeks, while secondary outcomes look at seizure-free days, overall impact, and safety throughout the trial duration, potentially spanning up to nearly five years.

Age: 2Years - 55YearsAll GendersPhase 3
71 locations
T

Actively Recruiting

Researchers are collecting and storing blood, DNA, and tissue samples from individuals diagnosed with tuberous sclerosis complex TSC or lymphangioleiomyomatosis LAM to support scientific research. These samples are linked to detailed clinical data that tracks the health impact of TSC over a persons lifetime, gathered both retrospectively and prospectively. This project aims to improve understanding of TSC and related conditions affecting various organs such as the brain, kidney, heart, lungs, and skin. Participants may provide biosamples through various methods, including blood draws, cheek swabs, genetic testing, or tissue donations following routine medical procedures. Samples can be collected at clinical study sites, participants homes, educational meetings, or through approved clinical partners using supplied kits and instructions. All collected samples are sent to a central biobank for processing, storage, and distribution to researchers after appropriate approvals. During participation, individuals contribute their samples and clinical information, which is stored in the TSC Natural History Database. Researchers monitor genetic variants through sequencing and may offer participants genetic counseling if they opt to receive their results. The project involves ongoing collection and sharing of biosamples and data, with an average follow-up of 15 years to study the natural history of TSC and LAM.

All AgesAll Genders
26 locations